Mesoblast (MESO) CFO awarded 650,000 options at A$2.90 strike, expiring 2032

Rhea-AI Filing Summary

Mesoblast Ltd reported that Chief Financial Officer James Michael O'Brien received a grant of 650,000 options to acquire Ordinary Shares. The options have an exercise price of A$2.90 per share, expire on December 22, 2032, and vest only if Mr. O'Brien achieves specified milestones.

Insights

Equity compensation analyst

CFO received performance-based options, a routine compensation grant.

Mesoblast Ltd granted CFO James Michael O'Brien 650,000 options with an exercise price of A$2.90 per share, expiring on December 22, 2032. The grant increases his potential equity exposure but does not involve open-market buying or selling.

The options vest only upon achievement of specified milestones, aligning part of his compensation with company and personal performance. Because this is a compensation award rather than a market transaction, it is generally viewed as neutral information for existing shareholders.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider OBRIEN JAMES MICHAEL

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Option (Right to buy)	650,000	$0.00	--

Holdings After Transaction: Option (Right to buy) — 650,000 shares (Direct, null)

Footnotes (1)

1. The exercise price for options is in Australian dollars. Granted on December 23, 2025. Vesting is dependent on Mr. O'Brien achieving certain milestones

Key Figures

Options granted: 650,000 options Exercise price: A$2.90 per share Expiration date: December 22, 2032 +2 more

5 metrics

Options granted 650,000 options Grant of options to CFO James Michael O'Brien

Exercise price A$2.90 per share Exercise price for the granted options, stated in Australian dollars

Expiration date December 22, 2032 Expiration date of the granted options

Underlying Ordinary Shares 650,000 shares Number of Ordinary Shares underlying the options

Grant date December 23, 2025 Date on which the options were granted

Key Terms

Option (Right to buy), exercise price, vesting

3 terms

Option (Right to buy) financial

"security_title: Option (Right to buy)"

exercise price financial

"The exercise price for options is in Australian dollars."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"Vesting is dependent on Mr. O'Brien achieving certain milestones"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/09/2026 - 09:54 PM Accepted by SEC EDGAR 07/09/2026 - 09:54 PM Learn about SEC filing dates

FAQ

What equity award did Mesoblast (MESO) grant to its CFO?

Mesoblast granted CFO James Michael O'Brien 650,000 options to acquire Ordinary Shares. These options form part of his equity-based compensation package and do not represent an open-market share purchase or sale.

What is the exercise price of the new Mesoblast (MESO) CFO options?

The granted options have an exercise price of A$2.90 per share. A footnote specifies that the exercise price is denominated in Australian dollars, affecting the cost if exercised in the future.

When do the Mesoblast (MESO) CFO options expire?

The options granted to Mesoblast’s CFO expire on December 22, 2032. After this date, any unexercised options will lapse, meaning they can no longer be used to acquire Ordinary Shares.

Are the Mesoblast (MESO) CFO options immediately vested?

No. A footnote states the options were granted on December 23, 2025 and that vesting depends on Mr. O'Brien achieving certain milestones. This makes the award performance-based rather than fully time-based.

How many Mesoblast (MESO) options does the CFO hold after this grant?

Following this transaction, the filing shows Mr. O'Brien holding 650,000 derivative securities (options) directly. These correspond to rights to acquire 650,000 Ordinary Shares if the options vest and are exercised.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OBRIEN JAMES MICHAEL

(Last) (First) (Middle)

LEVEL 38, 55 COLLINS STREET

(Street)

MELBOURNE VICTORIA 3000

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Issuer Name and Ticker or Trading Symbol
MESOBLAST LTD [ MESO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (Right to buy)	$2.9(1)	12/23/2025	07/07/2026	A		650,000		(2)	12/22/2032	Ordinary Shares	650,000	$0.00	650,000	D

Explanation of Responses:

1. The exercise price for options is in Australian dollars.

2. Granted on December 23, 2025. Vesting is dependent on Mr. O'Brien achieving certain milestones

	/s/ James Michael O'Brien	07/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)